SCHEMBL6918344

SCHEMBL6918344

CCCCCOc1ccnc(Cl)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.39
CYP2D6 P10635 3/20 0.39
NR5A1 Q13285 1/20 0.38
SOAT1 P35610 1/20 0.38
LTA4H P09960 2/20 0.37
NPC1 O15118 3/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
RAB9A P51151 1/20 0.37
HSD17B10 Q99714 1/20 0.37
MCHR1 Q99705 2/20 0.36
TLR8 Q9NR97 2/20 0.36
LMNA P02545 2/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
NUDT1 P36639 1/20 0.35
NFKB1 P19838 1/20 0.35
NFKB2 Q00653 1/20 0.35
RELA Q04206 1/20 0.35
MAPK8 P45983 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12391026 0.94 CYP2D6 (0.42) CYP3A4CYP2D6LTA4HNPC1SMN1; SMN2
SCHEMBL16885185 0.89 NUDT1 (0.37) CYP3A4LTA4HNPC1SMN1; SMN2RAB9A
SCHEMBL22576451 0.85 HTT (0.39) NPC1SMN1; SMN2RAB9AHSD17B10LMNA
SCHEMBL7783352 0.81 MAPK8 (0.46) CYP3A4CYP2D6NR5A1SOAT1LTA4H
SCHEMBL2016297 0.81 HTT (0.39) NPC1SMN1; SMN2RAB9AHSD17B10LMNA
SCHEMBL2221308 0.80 KDM4E (0.40) NPC1SMN1; SMN2RAB9ANUDT1NFKB1
SCHEMBL6283547 0.80 NUDT1 (0.57) MCHR1TLR8NUDT1
SCHEMBL2017242 0.79 TSHR (0.39) SMN1; SMN2HSD17B10NUDT1TSHR
SCHEMBL1400638 0.79 NUDT1 (0.35) NUDT1
SCHEMBL22576250 0.79 MAPT (0.44) SMN1; SMN2NUDT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6734304-B2 REACTING THE CORRESPONDING 4.6-DIHALOPYRIMIDINE COMPOUND WITH BASE; ONE POT PROCESS BAYER AKTIENGESELLSCHAFT (DE) 2004-05-11 US disclosed
US-20030092723-A1 Method for producing asymmetrical 4,6-bis(aryloxy)pyrimidine derivatives BAYER INTELLECTUAL PROPERTY GMBH (DE) 2003-05-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030092723-A1 Method for producing asymmetrical 4,6-bis(aryloxy)pyrimidine derivatives DPYD, TYMS, TYMP CYP3A4 43/4885CYP2D6 11/4885NR5A1 3146/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.